For research use only. Not for therapeutic Use.
SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC50 of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC50 of 0.15 μM[1][2].
SSAA09E3 blocks viral entry by inhibiting fusion of the viral membrane with the host cell membrane[1].
SSAA09E3 inhibits later stages of viral entry[2].
| Catalog Number | I012202 |
| CAS Number | 52869-18-8 |
| Synonyms | N-(9,10-dioxoanthracen-2-yl)benzamide |
| Molecular Formula | C21H13NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H13NO3/c23-19-15-8-4-5-9-16(15)20(24)18-12-14(10-11-17(18)19)22-21(25)13-6-2-1-3-7-13/h1-12H,(H,22,25) |
| InChIKey | SIGATAYQAZTAOH-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)C(=O)NC2=CC3=C(C=C2)C(=O)C4=CC=CC=C4C3=O |
| Reference | [1]. Ghosh AK, et al. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. ChemMedChem. 2020 Jun 4;15(11):907-932. [2]. Adedeji AO, et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013 Jul;87(14):8017-28. |
